Objective: To evaluate patterns of care for age-related macular degeneration following the introduction of vascular endothelial growth factor inhibitors.
T HE DEVELOPMENT OF VASCUlar endothelial growth factor (VEGF) inhibitors has revolutionized the treatment of age-related macular degeneration (AMD), the leading cause of blindness in Western nations. [1] [2] [3] The Minimally Classic/Occult Trial of the Anti-VEGF AntibodyRanibizumabintheTreatmentofNeovascularAMD 2 andtheAnti-VEGFAntibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD trial 3 have demonstrated that the VEGF inhibitor ranibizumab not only slows vision loss but also improves visual acuity in many patients with neovascular AMD.
During the progress of these pivotal trials, case series suggested that bevacizumab, a closely related VEGF inhibitor, might also dramatically improve outcomes for patients with AMD. 4 Because of the significantly lower cost and immediate availability of bevacizumab, it became the treatment of choice in many centers. However, off-label intravitreal injection of this drug has generated controversy worldwide. 1 Access to new VEGF inhibitor therapies may be limited by a number of factors, including regulatory approval, cost, and the necessity of administering these drugs via serial intravitreal injections under the care of an ophthalmologist. At a population level, the widespread uptake of drug therapies requiring direct physician administration has the potential to significantly affect the practice of many ophthalmologists, yet quantitative data describing the evolution of intravitreal injection procedure rates over time are lacking. To address this, we conducted a retrospective population-based study to evaluate developments in patterns of care for AMD.
METHODS
We studied monthly fee claims for intravitreal injections submitted to the Ontario Health Unique, encrypted identifiers and associated specialty codes were used to link injections to the ophthalmologists who administered them. We calculated each surgeon's annual intravitreal injection volume based on the number of claims submitted for each year.
We anticipated that intravitreal injections would become more frequent after the VEGF inhibitor bevacizumab received regulatory approval in Canada in September 2005. Although bevacizumab was licensed for use in colorectal cancer, offlabel intravitreal use of this drug for AMD was first described 4 in July 2005 and quickly became popular because of bevacizumab's immediate availability and low cost as compared with the VEGF inhibitor ranibizumab, which did not receive regulatory approval in Canada until June 2007.
1, 4 The study protocol was approved by the research ethics boards at Queen's University, Kingston, and Sunnybrook Health Sciences Centre, Toronto, both of which are in Ontario, Canada.
RESULTS
Following the regulatory approval of bevacizumab in September 2005, the rate of intravitreal injections in Ontario rapidly grew 8-fold to its peak level in November 2007 (growth from 3.5 to 25.9 injections per 100 000 Ontarians per month) (Figure 1 ). This striking upswing in injections preceded the availability of ranibizumab in Ontario by almost a year.
In contrast, the number of ophthalmologists performing injections rose more modestly from 39 (10% of all In 2007, more than 50% of intravitreal injections were performed by just 3% of Ontario's ophthalmologists (Figure 3) , and the monthly number of injections performed by this group of intensive service providers grew from 162 to 1436 between September 2005 and November 2007.
COMMENT
The development of VEGF inhibitors has ushered in an exciting era in the treatment of AMD. To our knowledge, this study is the first to quantify the dramatic uptake of these treatments at a population level. Strengths of our study include the large numbers of surgeons and procedures evaluated in our population-based data. We were unable to confirm which drug was administered with each injection because off-label drug use was not directly quantifiable. Nevertheless, our findings strongly suggest that off-label use of bevacizumab accounts for the vast majority of injection procedures in the period fol- lowing its regulatory approval for colorectal cancer in September 2005 and preceding regulatory approval of ranibizumab in June 2007. While the first VEGF inhibitor approved for AMD, pegaptanib sodium, received regulatory approval in Canada in May 2005, this drug is less effective than other anti-VEGF medications and is not commonly used. 1 We confirmed that very few prescriptions for pegaptanib were dispensed in Ontario during our study period (data not shown). Moreover, although there has been renewed interest in intravitreal injection of triamcinolone acetonide for retinal diseases, the relative contribution of this drug to the trends we document is also likely small. 6 Finally, the injection of intravitreal antibiotics is a relatively rare procedure and the rate of postoperative endophthalmitis in Ontario was stable over the study period. 7 As a result, these drugs have also contributed minimally to the rapid increase in intravitreal injection rates.
The magnitude of off-label bevacizumab use suggested by our findings has important implications. Recently, off-label intravitreal bevacizumab injections have been linked to an outbreak of severe intraocular inflammation. This Canadian-centered outbreak has attracted international attention and has prompted warnings from the US Food and Drug Administration and Health Canada. 8 However, reassuringly, this outbreak was linked to a single lot of medication and similar outbreaks have not been reported elsewhere. The closely related drug ranibizumab is specifically designed for intravitreal injection and has been approved for the treatment of AMD by the US Food and Drug Administration, Health Canada, and many other national regulatory agencies. However, the cost of ranibizumab has generated significant controversy as governments struggle to reach decisions on insurance coverage. Internationally, a growing number of countries, including the United States, the United Kingdom, and Australia, have introduced coverage for ranibizumab under publicly funded drug plans in specific circumstances. In March 2008, the Canadian Expert Drug Advisory Committee recommended that publicly funded provincial drug insurance programs should provide coverage for ranibizumab, and a number of provinces now provide such coverage.
Although the focus of our investigation was intravitreal injection rates, our data provide an opportunity to begin to evaluate the potential costs associated with the use of VEGF inhibitors at a population level (Table) . This cost analysis does not incorporate the comparative effectiveness and safety of ranibizumab and off-label bevacizumab, which remain the subjects of intense debate. As a result, the National Eye Institute is currently undertaking the Comparison of Age-Related Macular Degeneration Treatments Trials to provide comparative data on these 2 related VEGF inhibitors. 9 Our findings highlight the concentration of intravitreal injection procedures in the hands of relatively few ophthalmologists. New procedures often diffuse over time from a small group of early adopters to a broader section of physicians. However, the specialized skills required to diagnose and manage AMD, combined with limited access to necessary diagnostic testing equipment, may restrict such diffusion in this case. The remarkable number of injection procedures required with current administration regimens, together with the limited supply of ophthalmologists and retina subspecialists, has the potential to limit equitable access to intravitreal injections in some regions and may also negatively affect access to services for other vision-threatening eye conditions. 10, 11 Although this may be mitigated somewhat by decreased use of alternative treatments such as photodynamic therapy, the broader indications for VEGF inhibitors and the need for serial injections will nevertheless result in significant net increases in demand for retina services. Hence, further research is needed to quantify these effects and guide physician human resource projections and planning. 11 Moreover, efforts will be needed to search for alternative approaches to posteriorsegment drug delivery. 12 In summary, we have quantified a recent dramatic surge in intravitreal injection procedure rates. This rapid uptake preceded the availability of ranibizumab, strongly suggesting that off-label intravitreal injection of bevacizumab has been highly prevalent. Although this substitution provides great cost savings, establishing the efficacy and safety of bevacizumab will have to await outcomes of ongoing clinical trials. 
